-
2022 SHS Professor Chen Suning: Collaborate to improve the current situation of SM diagnosis and treatment, and pay attention to rare blood diseases
Time of Update: 2022-10-25
SM is a rare hematological disease, with the increase in detection rate in Europe and the United States gradually attracting attention, can you talk about the current status and challenges of SM diagnosis and treatment in China?Professor Chen SuningAt present, systemic mastocytosis (SM) in China has not been fully valued, domestic epidemiological data are not clear, with reference to Danish epidemiological data (annual incidence of 0.
-
The diagnostic history of a case of T-cell large granular lymphocytic leukemia
Time of Update: 2022-10-25
Hemomyeloid image: the proportion of T lymphocytes in the bone marrow is increased, combined with flow cytometry immunophenotyping can not exclude T-cell lymphoma (large granular T lymphocytic leukemia), but please rule out reactive changes first, please combine clinical, bone marrow smear and other examinations, and do TCR rearrangement examination.
-
2022 SHS stands at the head of the tide, strives to be the first, never gives up in cultivation, and continues the Xinhua chapter, and the 15th Suzhou Hematology Summit ended successfully!
Time of Update: 2022-10-21
From October 8 to 9, 2022, many top hematology experts at home and abroad gathered in Gusu City, the paradise on earth, to participate in the 15th Suzhou Hematology Summit. After more than ten years a
-
Micro Classroom No. 13 Professor Warburglar: Clinical management of daratumumab
Time of Update: 2022-10-21
Common methods and advantages and disadvantages of eliminating Dara blood transfusion interference5For patients treated with Vara with potential transfusion needs, the clinical management process recommended by expert consensus above should be referred to (Figure 4).
-
The 2022 SOHO ASTX727 combined with venetoclax is expected to improve the prognosis of patients with relapsed or treatment-naïve AML
Time of Update: 2022-10-21
Editor: moly Review: Quinta Typesetting: moly Execution: molyPoke "Read Original" to see moreThe all-oral regimen of ASTX727 plus ven is safe and feasible in advanced elderly patients with AML and has significant efficacy in patients who are not candidates for chemotherapy in FL and R/R cohorts.
-
Blood Friends New Life Live Up to Shaohua I Continuation of Hua Chapter The sound has not fallen, and the Hemophilia Frontier Progress Tour (Beijing Station) has been successfully held!
Time of Update: 2022-10-21
Editor: Valamor Review: Janet Typesetting: moly Execution: molyPoke "Read Original" to see more conference topics, not to be missedKey point two: Even if the majority of Chinese hemophilia patients are treated prophylacticallyAHEAD study is a prospective, non-interventional, multicenter clinical trial conducted in 22 countries, and a total of 141 patients were included in the Chinese subgroup 。 The results showed that even after receiving preventive treatment, the overall proportion of patients with bleeding events was as high as 75.
-
2022 SHS Professor Wu Depei: Strive to promote the standardized diagnosis and treatment of PNH, pay attention to rare diseases, and do not let love be rare
Time of Update: 2022-10-21
On this occasion, Yimaitong specially invited Professor Wu Depei from the First Affiliated Hospital of Soochow University to interpret the hot topics of the Suzhou Hematology Summit, the work progress and plans of the Hematology Rare Disease Working Group and the PNH Diagnosis and Treatment Collaboration Group, so as to feed readers!
-
Efficacy of azacitidine combined with pevonedistat in high-risk MDS/CMML and low-blast AML patients
Time of Update: 2022-10-20
Myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) are myelotumors with common mutated genes and biological clinical features. They are characteri
-
Review: Long-term complications and management of hematopoietic stem cell transplant patients
Time of Update: 2022-10-20
Patients with allogeneic HSCT have difficulty returning to pre-transplant status, have a unique disease risk spectrum, and must be monitored for long-term transplant complications, including chronic graft-versus-host disease (GVHD), multi-organ complications, and secondary malignancies.
-
Preliminary safety results of the introduction phase of the 2022 SOHO| Phase III LOTIS-5 trial: Lonca combined with rituximab for the treatment of R/R DLLBCL
Time of Update: 2022-10-20
Editor: moly Review: Quinta Typesetting: moly Execution: molyPoke "Read Original" to see more03Research conclusionLonca-R showed no new safety signals in patients with R/R DLBCL in the safety lead-in phase and had good antitumor activity.
-
To improve MM treatment adherence, think in terms of these aspects
Time of Update: 2022-10-20
And how can it be effectively improved?01What are the new findings of the first systematic review and meta-analysis to quantify MM oral medication adherence and discontinuation rates?A systematic review and meta-analysis published this year in Clinical Lymphoma, Myeloma and Leukemia evaluated adherence and persistence to oral anti-tumor therapies (OOTs) in real-world MM patients [4].
-
2022 SHS Professor Ma Jun: Take the helm of innovation, raise the sail of precision, the current situation and development of precision oncology in China
Time of Update: 2022-10-20
Yimaitong: China has made gratifying achievements in the field of precision cancer treatment, how can the results of precision medicine be extended to a wide range of clinical applications in the future?Professor Ma JunAlthough China has become the world's second largest economy, we still belong to the third world countries from the perspective of scientific and technological innovation.
-
Express treatment of hemophilia A, FDA accepted marketing applications for potential blockbuster gene therapy
Time of Update: 2022-10-20
▲If you have any business needs, please long press to scan the QR code above, or▎WuXi AppTec content team editorBioMarin Pharmaceutical announced that the US FDA has accepted the company's resubmitted biologics license application (BLA) for valoctocogene roxaparvovec, an AAV gene therapy under investigation, for the treatment of adult patients with severe hemophilia A.
-
Two major advances in the treatment of hemophilia A guided by PK: guideline / consensus development + research data release
Time of Update: 2022-10-20
In recent years, with the development of medical technology and innovation in the field of hemophilia treatment, factor replacement therapy has gradually developed into the era of individualized preve
-
2022 SHS Professor Liu Qiqi: Application status and development prospects of hematopoietic stem cell transplantation
Time of Update: 2022-10-20
What are the main problems and difficulties?Professor Liu QiqiAt present, China's HSCT technology is at the forefront of the world, but the proportion of elderly patients receiving HSCT in China is relatively low, and there is still a certain gap compared with European and American countries.
-
J Clin Med: Risk factors for infection in patients with relapsed/refractory multiple myeloma treated with lenalidomide and dexamethasone (Rd) regimens: real results from a large single-center study
Time of Update: 2022-10-19
Risk Factors of Infection in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone (Rd) Regimen: Real-Life Results of a Large Single-Center Study.
Risk Factors of Infection in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone (Rd) Regimen: Real-Life Results of a Large Single-Center Study.
-
The veteran "microscope" explores the true culprit of anemia
Time of Update: 2022-10-19
To diagnose these diseases, blood routine and reticulocyte count should first be used to determine the diagnosis, degree and type of anemia; Then select special tests according to clinical data, such as folic acid/B12 measurement, bone marrow examination, body iron status indicators, hemolysis test, hemoglobin electrophoresis, flow cytometry and gene analysis, etc.
-
SOHO 2022: Zebrutinib has better ORR and PFS benefits than ibrutinib in patients with relapsed/refractory CLL/SLL disease
Time of Update: 2022-10-19
1% of patients in the zebrutinib and ibrutinib groups, respectively, had received more than three prior lines of treatment.
1% of patients in the zebrutinib and ibrutinib groups, respectively, had received more than three prior lines of treatment.
-
Nat Genet: Resolving the effect of DNMT3A R882 mutation in human clonal hematopoiesis based on single-cell multiomics technology
Time of Update: 2022-10-19
Recently, the team of Weill Cornell Medical College in the United States and the research team of Dana-Farber Cancer Institute published a report in Nature Genetics entitled "Single-cell multi-omics of human clonal hematopoiesis reveals that DNMT3A R882 mutations perturb early progenitor states.
-
SOHO 2022: Pacritinib improves transfusion-dependent anemia by inhibiting ACVR1 in myelofibrosis
Time of Update: 2022-10-19
FDA approval for marketing, see: FDA approves new myelofibrosis drug pacritinibAccording to the results of a retrospective analysis of the Phase 3 PERSIST-2 trial (NCT02055781) presented at the 10th Annual Meeting of the American Society of Hematology-Oncology (SOHO), pacritinib treatment improved transfusion dependence and hemoglobin in patients with myelofibrosis.
